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Adrenocorticotropic hormone, but not trilostane, causes severe
adrenal hemorrhage, vacuolization, and apoptosis in rats
Abstract
Adrenal necrosis has been reported as a complication of trilostane application in dogs with
hyperadrenocorticism. One suspicion was that necrosis results from the increase of adrenocorticotropic
hormone (ACTH) during trilostane therapy. The aim of the current study was to assess the effects of
ACTH and trilostane on adrenal glands of rats. For experiment 1, 36 rats were divided into 6 groups.
Groups 1.1 to 1.4 received ACTH in different doses (60, 40, 20, and 10 μg/d) infused subcutaneously
with osmotic minipumps for 16 wk. Group 1.5 received saline, and group 1.6 received no therapy. For
experiment 2, 24 rats were divided into 3 groups. Group 2.1 and 2.2 received 5 and 50 mg/kg
trilostane/d orally mixed into chocolate pudding for 16 wk. Eight control rats received pudding alone. At
the end of the experiments, adrenal glands were assessed for necrosis by histology and
immunohistochemistry; levels of endogenous ACTH and nucleosomes were assessed in the blood. Rats
treated with 60 μg ACTH/d showed more hemorrhage and vacuolization and increased numbers of
apoptotic cells in the adrenal glands than rats treated with 20 or 10 μg ACTH/d, trilostane, or control
rats. Rats treated with 60 μg ACTH/d had a higher amount of nucleosomes in the blood compared with
rats treated with 10 μg ACTH/d, trilostane, or saline. We conclude that in healthy rats ACTH, but not
trilostane, causes adrenal degeneration in a dose-dependent manner. Results of this study support the
hypothesis that adrenal gland lesions seen in trilostane-treated dogs are caused by ACTH and not by
trilostane.
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Adrenal necrosis has been reported as a complication of trilostane application in dogs with 
hyperadrenocorticism. One suspicion was that necrosis results from the increase of 
adrenocorticotropic hormone (ACTH) during trilostane therapy. Aim of the current study was 
to assess the effects of ACTH and trilostane on adrenal glands of rats. For experiment 1, 36 
rats were divided into six groups. Groups 1.1-1.4 received ACTH in different doses (60, 40, 
20 and 10 µg/d) infused subcutaneously with osmotic minipumps for 16 wk. Group 1.5 
received saline and group 1.6 no therapy. For experiment 2, 24 rats were divided into 3 
groups. Group 2.1 and 2.2 received 5 and 50 mg/kg trilostane/d orally mixed into chocolate 
pudding for 16 wk. Eight control rats received pudding alone. At the end of the experiments, 
adrenal glands were assessed for necrosis by histology and immunohistochemistry; levels of 
endogenous ACTH and nucleosomes were assessed in the blood. Rats treated with 60 µg 
ACTH/d showed more hemorrhage and vacuolization and increased numbers of apoptotic 
cells in the adrenal glands than rats treated with 20 or 10 µg ACTH/d, trilostane or control 
rats. Rats treated with 60 µg ACTH/d had a higher amount of nucleosomes in the blood 
compared to rats treated with 10 µg ACTH/d, trilostane or saline. We conclude that in healthy 
rats ACTH, but not trilostane, causes adrenal degeneration in a dose-dependent manner. 
Results of this study support the hypothesis that adrenal gland lesions seen in trilostane-
treated dogs are caused by ACTH and not trilostane. 
Key words: Adrenocorticotropic hormone – adrenal necrosis – trilostane - rats
 2
1. Introduction 45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
Trilostane is a competitive inhibitor of the 3β-hydroxysteroid dehydrogenase/Δ5,4-isomerase 
enzyme system (3β-HSD) [1-3], which is essential for the biosynthesis of all classes of steroid 
hormones. Due to its reliable clinical efficacy, trilostane is widely used for the treatment of 
dogs with pituitary-dependent hyperadrenocorticism (PDH). Trilostane therapy decreases 
cortisol and, as a result of the reduced negative feedback, increases endogenous 
adrenocorticotropic hormone (ACTH) concentration [4-8]. When dosed optimally, side 
effects during trilostane therapy are rare. However, recently, adrenal necrosis has been 
described in trilostane-treated dogs with PDH [9-11]. Necrosis of the adrenal cortex cannot be 
explained by the known enzyme-inhibiting mechanism of trilostane [1]; the cell death was 
therefore attributed most probably to either the hypersecretion of ACTH or to a direct action 
of trilostane or one of its metabolites [9-11].  
ACTH is secreted by the anterior pituitary gland; its primary function is to stimulate the 
production of glucocorticoids from the adrenal cortex. The use of a chemically synthesized 
analogue of the natural ACTH molecule is widespread in human and veterinary medicine to 
diagnose and monitor adrenal diseases. Although ACTH is an important physiologic 
hormone, the suspicion exists that it can have deleterious effects if present in excessive 
amounts in animals and humans. First, in human medicine, both, stress-mediated increases in 
ACTH during severe infections and septicemia and the therapeutic administration of huge 
doses (> 1 mg/d) of exogenous ACTH seemed associated with the risk of adrenal hemorrhage 
and necrosis [12-14]. Second, rats treated intermittently with high doses of a purified bovine 
ACTH preparation, showed degeneration, focal necrosis and hemorrhage in the adrenal 
glands [15]. Later studies, however, using lower doses of synthetic ACTH in rats, did not 
report such side effects [16-18]. These discrepancies are striking, but possible explanations 
are the dose differences or the chemical purity of the newer synthetic preparations.  
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Systematic studies on the influence of ACTH on adrenal cells using synthetic ACTH in 
different concentration have not been published. Furthermore, long-term studies in animals 
using high doses of trilostane and evaluating adrenal changes are lacking. As ACTH 
concentrations during trilostane therapy can increase impressively in dogs, it has been 
hypothesized by several researchers that adrenal necrosis seen in trilostane-treated dogs with 
PDH could be attributed to the increased ACTH concentration [9-11,19]. To gain further 
insight into the effects of ACTH and trilostane on adrenal cells, the authors intended to 
evaluate their effects in an experimental animal model. Therefore, the goals of the study 
reported here were to evaluate the effects of different doses of synthetic ACTH and the effects 
of different doses of trilostane on adrenal glands of healthy rats. 
 
2. Materials and methods 
2.1. Animals and experimental procedures 
All studies were approved by the Cantonal Veterinary Office of Zurich and conducted in 
accordance with guidelines established by the Animal Welfare Act of Switzerland 
(permission number: 34/2008). 
For experiment 1, 36 adult male Sprague-Dawley rats (Charles River, Sulzfeld, Germany), 
weighing 224-272 g (median 255) were used. Rats were housed in pairs, under 12:12 h light-
dark cycle (light onset at 8:00 am), at 23 °C, and maintained on a standard diet (Rat Chow; 
Charles River) and tap water ad libitum for the duration of the experiment. The rats were 
divided into six groups. The rats of four groups were infused subcutaneously (Alzet osmotic 
pumps Mod 2ML4; Alzet, Cupertino, CA, USA) for up to 16 wk with synthetic human ACTH 
(Synacthen® Depot; concentration: 2 mg/ml; Novartis International AG, Basel, Switzerland) 
dissolved in 0.9 % NaCl; group 1.1 (n=9), 1.2 (n=5), 1.3 (n=5) and 1.4 (n=5) received 60, 40, 
20 and 10 µg ACTH/d, respectively. Animals of group 1.5 (n=6) were infused for 16 wk with 
0.9 % NaCl, and animals of group 1.6 (n=6) did not receive any treatment. For the pump 
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implantation, the rats received 2 mg/kg meloxicam (Metacam®, Boehringer Ingelheim GmbH, 
Basel, Switzerland) subcutaneously and were subsequently anesthetized with isoflurane 
(Abbott AG, Baar, Switzerland). Pumps were exchanged every 4 wk. 
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For experiment 2, 24 adult male Sprague-Dawley rats (Janvier, S.A.S., Le Genest-St-Isle, 
France), weighing 284-334 g (median 310) were used. Rats were housed in pairs, under  
12:12 h light-dark cycle (light onset at 22:00 pm) and at 23 °C. During the dark period rats 
were fed a chocolate pudding (Ensure plus crème, Abbott Laboratories, Saint Florent de 
Vallée, France) with or without trilostane in addition to the standard diet (Rat Chow; Charles 
River) and tap water ad libitum. During light period rats were fasted by removing the standard 
diet; tap water was available ad libitum. The rats were divided into three groups. Animals in 
group 2.1 (n=8) and 2.2 (n=8) received 5 and 50 mg/kg trilostane/d orally mixed in the 
chocolate pudding and animals in group 2.3 (n=8) received chocolate pudding only.  
During both experiments, the clinical condition and body weight of each rat were checked 
daily. The amount of food and water consumed per cage was determined every other day. If 
the body weight of a rat decreased to less than 30 % of the average median body weight of the 
control rats, the rat was euthanized before the end of the experiment because of animal 
welfare reasons.  
At the beginning and at the end of the experiments animals were anesthetized with isoflurane 
and serum and EDTA-plasma was collected by sublingual venous puncture. At the end of the 
two experiments, the adrenal glands were collected within 30 min of euthanasia and one was 
fixed for 24-48 h in 4 % neutral buffered formaldehyde and the other snap frozen in liquid 
nitrogen and stored at -80 ºC. 
 
2.2. Histological examinations 
Adrenal glands were fixed in 4 % neutral buffered formaldehyde and embedded in paraffin by 
routine procedures. Sections (3-5 μm) were stained with hematoxylin and eosin by a routine 
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procedure or used for immunostaining. The latter were mounted on positively charged glass 
slides (Superfrost®, Erie Scientific Company, Portsmouth, NH) and dried overnight at 37 °C. 
Sections through the adrenal glands were orientated on the transversal plane, and all the 
anatomical layers (zona glomerulosa/arcuata, zona fasciculata, zona reticularis and medulla) 
were evaluated histopathologically. The animals were numbered by the first author (WB) and 
were evaluated blinded by an experienced pathologist (FG). For statistical analysis, the 
histologic lesions in the adrenal cortex were quantified using a scoring system comprising a 
measure for hyperemia/hemorrhage (from 1-4: 1 – normal blood content; 2 – focal or 
multifocal hyperemia; 3 – moderate diffuse hyperemia and hemorrhage; 4 – severe diffuse 
hyperemia and hemorrhage), a measure for the degree of cytoplasmic vacuolization (from 1-3: 
1 – normal; 2 – moderately increased; 3 – markedly increased), and a measure for the 
occurrence of clusters of neutrophils (from 1-2: 1 – not present; 2 – present). A cumulative 
score calculated by adding up the 3 single scores was determined for each animal and used for 
the statistical analysis.  
 
2.3. Immunohistochemical analyses 
Apoptotic cells were detected and quantified in the adrenal glands using 
immunohistochemical stains for cleaved lamin A and cleaved caspase-3. Antigen specific 
rabbit polyclonal antibodies (lamin A: 2035, Cell Signaling Technology, Bioconcept, 
Allschwil, Switzerland; caspase-3: AF835, R&D Systems, Abingdon, UK) were applied 
following a previously described immunoperoxidase protocol with minor modifications [20]. 
Briefly, antigen retrieval was done heating the sections for 20 min at 98 °C in EDTA buffer, 
pH 9 (lamin A) or for 2 min at 125 °C in citrate buffer, pH 7 (caspase-3). The primary 
antibody was applied for 1h at room temperature, and the reaction was visualized using a 
Detection Kit (Dako Cytomation, Zug, Switzerland) according to the manufacturer’s 
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instructions. Canine keratinocytes treated with UV-irradiation and rat lymph node tissue were 
used as positive controls, while the primary antibody was omitted as a negative control. 
To evaluate the immunoreactivity for cleaved lamin A and cleaved caspase-3, 10 digital 
microscopic images were created from the cortical region in each adrenal gland immunostain 
following a predetermined scheme, using an AxioCam digital camera (Carl Zeiss AG, 
Feldbach, Switzerland) and a 40 x objective lens. Each microscopic image was assessed 
manually by counting all labelled cells displaying apoptotic morphology; groups of closely 
lying labelled apoptotic cell bodies were counted as one cell. For each rat, the number of 
apoptotic cells was determined as the average of the counts of two blinded investigators (WB, 
NS).  
 
2.4. Endocrinological analyses 
Blood levels of endogenous ACTH were determined using a chemiluminescent immunoassay 
system (DPC Immulite® One, Siemens Healthcare Diagnostics GmbH, Switzerland).  The 
detection limit of the ACTH assay was 2.2 pmol/L.  
The slope of the regression equations and the r2 were close to 1 for each dilution. The intra-
assay coefficient of variation (CV) was 8.3, 1.4 and 2.3 % for samples with 3, 13.5 and 118 
pmol/L ACTH, respectively. The inter-assay coefficient of variation (CV) was 22.3, 8.8 and 
4.7 % for samples with 3.6, 39.4 and 117 pmol/L ACTH, respectively.  
 
2.5. Histone-complexed DNA fragments (nucleosomes)in blood 
For relative quantification of histone-complexed DNA fragments the cell death detection 
ELISAplus (Roche Applied Science, Rotkreuz, Switzerland) was used. All measurements were 
done in serum. 
 
2.6. Statistic analysis 
 7
173 
174 
175 
176 
177 
178 
179 
180 
181 
182 
183 
184 
185 
186 
187 
188 
189 
190 
191 
192 
193 
194 
195 
196 
197 
Results were analyzed by use of nonparametric statistical methods (SPSS 11.0 for Windows, 
SPSS Inc, Chicago, Ill, USA and GraphPad Prism 4, San Diego, California, USA). Ranges 
and median values are reported. Differences between groups were tested by use of Kruskal-
Wallis H test and Dunn’s post test. Differences within groups between the start and the end of 
the experiment were tested by use of Wilcoxon matched pairs test. Differences were 
considered significant at values of p ≤ 0.05.  
 
3. Results 
3.1. Body weight and clinical parameters 
3.1.1 Experiment 1: 
Food intake was significantly lower and water intake significantly higher in ACTH-treated 
rats during the experiment compared to rats treated with saline (food intake/cage/d (2 rats): 
ACTH-treated rats: median: 54 g, range: 46-65, rats treated with saline: median: 59 g, range: 
49-68, p<0.0001; water intake/cage/d (2 rats): ACTH-treated rats: median: 72 ml, range: 55-
84, rats treated with saline: median: 63 ml, range: 55-78, p<0.0001).  
All ACTH-treated rats showed a significantly lower body weight gain compared to rats 
treated with saline (p<0.0001) (Figure 1a). Nine of nine, 2/5, 1/5 and 0/5 rats treated with 60, 
40, 20 and 10 μg ACTH/d had to be euthanized before the end of the experiment, because the 
difference in body weight compared to the control animals (rats treated with saline) exceeded 
the set threshold (> 30 % below controls).  
3.1.2. Experiment 2: 
There was no difference in food or water intake and body weight gain between trilostane 
treated and control rats (Figure 1b). No rat had to be euthanized before the end of the 
experiment.  
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3.2.1. Experiment 1 
Histological changes were found only in the adrenal cortex. They were particularly 
pronounced in the group treated with 60 μg ACTH/d and were found only occasionally and to 
a minor extent in some animals of the other groups. The major changes consisted in strong 
dilatation of the sinusoids, associated with a very pronounced hyperemia combined, to some 
extent, with extravasation of erythrocytes (Figures 2). Another feature that was prominent in 
several animals in the group treated with 60 μg ACTH/d and that was only occasionally 
evident in the low-dose (10-40 μg ACTH/d) group and absent in both control groups, was the 
occurrence of predominantly large cytoplasmic vacuoles filling most of the cell cytoplasm 
(Figures 2). Further, small clusters of neutrophils, mostly located in the dilated sinusoids and 
to a lesser extent outside of the capillaries were observed only in animals treated with 60 µg 
ACTH/d. Finally, there was a loss of basophilia of the zona reticularis, caused by an increase 
in the cytoplasmic volume and an apparent increase in the size of the nucleus; these cells of 
the zona reticularis were indistinguishable from those in the zona fasciculata. This finding 
was present in all animals treated with high dose of ACTH (60 µg/d), 1/5 animals treated with 
40 µg ACTH/d and 2/5 animals treated with 20 µg ACTH/d. In all other animals, cells in the 
zona reticularis were clearly distinguishable from those in the zona fasciculata.  
Overall, rats treated with 60 µg ACTH/d had a significantly higher cumulative histologic 
score than rats treated with 20 or 10 µg ACTH/d, rats treated with saline or rats receiving no 
therapy (p=0.0001) (Figure 3a).  
 
3.2.2. Experiment 2 
A slight degree of hyperemia in the adrenal cortex was present in 1/8 animals treated with 5 
mg/kg trilostane/d, in 2/8 animals treated with 50 mg/kg trilostane/d and in 2/8 control 
animals. The degree of vacuolization of adrenal cortical cells was similar in all groups and 
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similar to the control animals in experiment 1. There were no clusters of neutrophils in any of 
the tissues, while the zona reticularis and the zona fasciculata could be easily distinguished in 
all animals.  
There was no difference in the cumulative histologic score between rats treated with trilostane 
and control rats (Figure 3b). 
 
3.3. Immunohistochemical analyses 
3.3.1. Experiment 1 
Cellular structures immunolabelled for lamin A mostly consisted of small groups of apoptotic 
cell bodies and occasionally of individual intact adrenal cortical cells showing early features 
of apoptotic cell death. The former showed a diffuse labelling, while the latter showed either 
diffuse or nuclear labelling (Figure 4). Immunohistochemical stains for cleaved caspase-3 
resulted in diffuse labelling of apoptotic bodies.  
Animals treated with 60 µg ACTH/d had a significantly higher number of lamin A positive 
cells in the adrenal cortex than rats treated with 20 and 10 µg ACTH/d, rats treated with saline 
and rats receiving no therapy (p=0.004) (Figure 5a). 
Animals treated with 60 μg ACTH/d had a significantly higher number of caspase-3 positive 
cells in the adrenal cortex than rats treated with 10 µg ACTH/d and control rats receiving no 
therapy (p=0.003) (Figure 5c). 
3.3.2. Experiment 2 
There was no significant difference in the number of lamin A or caspase-3 positive cells 
between trilostane treated rats and control rats (Figure 5b and d).  
 
3.4. Endogenous ACTH concentrations 
3.4.1. Experiment 1 
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The endogenous ACTH concentration was below the detection limit in rats treated with 
synthetic ACTH. In the rats treated with saline the median (range) endogenous ACTH 
concentration was 38.5 pmol/L (20.8-149) at the start and 24.2 pmol/L (20.5-55.6) at the end 
of the experiment. There was no significant difference between the two measurements. In rats 
receiving no therapy the median (range) endogenous ACTH concentration at the end of the 
experiment was 11.6 pmol/L (6.2-23.8).  ACTH concentrations at the end of the experiment 
were significantly lower in rats with no therapy than in rats treated with saline (p=0.03). 
3.4.2. Experiment 2 
Endogenous ACTH concentrations did not change significantly during trilostane therapy.   
Median (range) endogenous ACTH concentrations at the start of the study were 29 pmol/L 
(23.8-52.6), 43.6 pmol/L (14.2-53.7), and 53.1 pmol/L (20.1-100) for rats treated with 5 
mg/kg trilostane/d, 50 mg/kg trilostane/d and control rats, respectively.  Median (range) 
endogenous ACTH concentration at the end of the study were 18.2 pmol/L (10.8-61.1), 21.7 
pmol/L (6.7-50), and 49.2 pmol/L (22-85) for rats treated with 5 mg/kg trilostane/d, 50 mg/kg 
trilostane/d and control rats, respectively. 
 
3.5. Levels of histone-complexed DNA fragments (nucleosomes) in blood 
3.5.1. Experiment 1 
Rats treated with 60 µg ACTH/d had a significantly higher amount of histone-complexed 
DNA fragments in the blood compared to rats treated with 10 µg ACTH/d or saline (p=0.03) 
(Figure 6).  
3.5.2. Experiment 2 
There was no difference in the amount of histone-complexed DNA fragments in the blood 
between trilostane-treated rats and control rats. 
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Treatment of rats with ACTH led to severe hemorrhage and vacuolization within the adrenal 
cortex in a dose-dependent manner. These findings are in agreement with a previous study, 
where treatment of rats with purified bovine ACTH resulted in similar histologic alterations 
[15]. In contrast, later studies in rats did not report adrenal damage after ACTH administration 
[16,18]. Of note, in the latter studies (as in our study), synthetic ACTH was used and 
additionally much lower doses (µg ACTH/d) than the ones used in the study of Wilbur and 
Rich (mg ACTH/d) were administered. Hence, it seemed unclear, if the reported deleterious 
effects of the purified bovine ACTH in the study of Wilbur and Rich were related to the 
nature of the product or to the dose of ACTH. Our study proves that synthetic ACTH is 
capable to induce severe adrenal damage, and that the adrenal changes caused by ACTH are 
dose-dependent. The dose dependency may explain why doses up to 20 µg ACTH/d, as used 
in the study of Miskowiak et al. and that of Sawchenko and Arias, did not induce adrenal 
damage [16,17]. That the ACTH dose is a crucial factor for the induction of adrenal damage is 
supported by the human literature. In humans, intravenous administration of huge doses of 
ACTH (1.2 mg/d) seemed associated with the risk of adrenocortical hemorrhagic necrosis and 
hypocortisolism [12,13]. 
In addition to the hemorrhage and vacuolisation, treatment with ACTH resulted in a 
significant increase in the numbers of apoptotic cells within the adrenal cortex. Presence of 
apoptosis was assessed by immunohistochemistry against neoepitopes of cleaved lamin A and 
cleaved caspase-3 [21]. Caspase-3 is a critical effector caspase, expressed in most cells and 
activated through cleavage in response to nearly all apoptosis triggers [22]. Lamin A is a 
ubiquitously expressed nuclear protein cleaved in a caspase-dependent manner during 
apoptosis [23,24]. Both methods showed significant differences between groups. However, 
immunolabeling of cleaved caspase-3 was more difficult to handle and to score and resulted 
in a higher inter-investigator variability than immunolabeling of cleaved lamin A. In addition, 
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the latter method indicated that apoptotic cells comprised adrenalcortical cells. Thus, 
immunohistochemistry for cleaved lamin A appears to be a simple and reliable method to 
detect apoptotic cells within adrenal glands.   
Clinically the ACTH-treated rats showed a significantly decreased food intake and a 
significantly blunted weight increase compared to the rats treated with saline. As both the 
blunted weight gain and the adrenal changes were dose-dependent a direct association 
between the two seems most likely. Indeed, the absence of glucocorticoids in rats (induced by 
adrenalectomy) was shown to reduce food consumption and body weight gain [25-27].  
To evaluate the effect of trilostane on adrenal glands, rats were treated with two different 
doses of trilostane in a second experiment. Our results show that in rats, trilostane in a dose 
up to 50mg/kg, does not induce adrenal necrosis. Unfortunately, 50 mg/kg was the highest 
trilostane dose accepted by the rats within the chocolate pudding. The authors are completely 
aware that a higher trilostane dose would have been desirable to definitively prove that 
trilostane doesn’t induce adrenal damage. Other researchers, however, used doses up to 300 
mg/kg trilostane/d in rats and reported a dose-dependent increase in adrenal weight, but no 
adrenal necrosis [1,28,29]. Notably, our study is the first study to report long-term therapy 
with trilostane (4 months), as in all other studies trilostane was administered for only 7-21 
days.  
Before the results of this study are applied to dogs, two drawbacks have to be discussed. The 
first and most obvious is a potential species-specific effect. It is known that the sensitivity to a 
specific drug varies among species. Trilostane inhibits the 3β-HSD in dogs and rats and leads 
to a decrease in cortisol/corticosterone concentrations and an increase in (17α-OH-) 
pregnenolone concentrations [1,8]. Rats, however, seem to tolerate much higher doses, as no 
signs of hypoadrenocorticism occurred with doses up to 300 mg/kg/d for 2 wk [1,28]. In dogs, 
the recommended dose to treat PDH is 2-5 mg/kg/d. In the present study we tried to take this 
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different sensitivity into account, by using two trilostane doses, one that is recommended for 
clinical use in dogs and a second one which is 10times higher.  
The second drawback of the study presented here is the use of healthy rats. Normal adrenal 
glands may react differently to a specific drug than hyperplastic adrenal glands, as seen in 
animals with PDH. However, because impressive differences were found between the 
treatment with ACTH and that with trilostane, the authors strongly believe that this study 
gives enough evidence that not trilostane per se but ACTH is responsible for the adrenal 
damage seen in dogs with PDH treated with trilostane.  
In this study synthetic human ACTH was used. One may argue that endogenous, species-
specific ACTH may not have the same deleterious effects. However, the suspicion that even 
endogenous ACTH in high concentrations can be dangerous comes from human medicine. 
Stress-mediated increased ACTH-secretion is presumed to be one factor leading to adrenal 
hemorrhage and necrosis in individuals with severe infections, septicemia or other illnesses 
such as burns [14].  
Endogenous ACTH concentration can increase remarkably in dogs with PDH treated with 
trilostane. In the rats of this study ACTH concentration seemed to decrease during trilostane 
therapy, although the change was not statistically significant. This contrasts the results of a 
study with young male rats, which had been treated with 30 mg/kg trilostane PO daily for 3 
wk. Trilostane therapy led to a significant decrease in basal corticosterone and a significant 
increase in ACTH concentration [29]. However, two other studies demonstrate that the 
adrenal response to trilostane in rats is variable. First, trilostane did not influence basal 
corticosterone levels in doses up to 200 mg/kg in one study [1]. A second study showed that 
sex differences in the adrenal response to trilostane exist. In young female rats trilostane 
lowered peak plasma corticosterone concentrations in a dose-dependent manner. In male rats, 
plasma corticosterone levels were reduced only by a very high dose of trilostane (200 mg/kg), 
while lower doses (2-8 mg/kg) actually increased them [30]. The lacking increase of ACTH 
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concentrations in the rats of our study may indicate that the basal corticosterone 
concentrations were not significantly influenced by the two trilostane doses used. As 
discussed before the highest trilostane dose accepted by the rats within the chocolate pudding 
was 50 mg/kg. That a higher dose of trilostane (e.g. 300 mg/kg) would have induced adrenal 
damage can’t be excluded. However, this seems less likely, as on one hand, adrenal damage 
induced by ACTH was very rapid in onset and grave and on the other hand, adrenal necrosis 
hasn’t been reported with short-term trilostane doses up to 300 mg/kg. The lacking increase in 
ACTH concentrations in this study can also be seen as benefit, as the effects of trilostane and 
ACTH on adrenal cells could thus be truly distinguished.  
In the clinical situation it would be very important to recognize patients with a risk for adrenal 
necrosis as soon as possible. Hence, a blood derived marker directing the clinician’s attention 
towards adrenal necrosis would be helpful. Histone-complexed DNA fragments or 
nucleosomes are cell death products that are elevated in serum of patients with diseases that 
are associated with massive cell destruction (e.g. malignant tumors, acute inflammation, 
autoimmune disease) [31-33]. To test if adrenal cell death induced by ACTH causes an 
increase in nucleosomes in blood, the concentration of nucleosomes was assessed in this 
study. Rats treated with 60 µg ACTH/d had a significantly higher amount of nucleosomes 
within the blood than rats treated with 10 µg ACTH/d or rats treated with saline. These are 
promising results as they may indicate that the measurement of nucleosomes in the peripheral 
blood may be a clinically useful marker to early recognize adrenal damage.  
In conclusion, this study shows that treatment of rats with synthetic ACTH leads to severe 
adrenal hemorrhage and vacuolisation and increased circulating levels of histone-complexed 
DNA fragments. Further, the results of this study support the hypothesis that the adrenal gland 
lesions seen in trilostane treated dogs with PDH may be caused by elevated ACTH and not by 
trilostane per se. Further studies are needed to bring these findings into a clinical setting in 
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dogs and to evaluate nucleosomes as a blood-marker for trilostane-induced adrenal 
degeneration. 
 
5. Acknowledgements 
W. Burkhardt was supported by the Forschungskredit of the University of Zurich, 2007, 
awarded to N.S. Sieber-Ruckstuhl. N. Aldajarov is recipient of a Swiss Government ESKAS 
scholarship (Nr. 2007.0393). Part of the study was performed using the logistics of the Centre 
of Clinical Studies at the Vetsuisse Faculty of the University of Zurich.  
 
 
 
 
  
 16
References 389 
390 
391 
392 
393 
394 
395 
396 
397 
398 
399 
400 
401 
402 
403 
404 
405 
406 
407 
408 
409 
410 
411 
412 
413 
[1] Potts GO, Creange JE, Harding HR, Schane HP. Trilostane, an orally active inhibitor 
of steroid biosynthesis. Steroids. 1978;32(2):257-267. 
[2] Schane HP, Potts GO, Creange JE. Inhibition of ovarian, placental, and adrenal 
steroidogenesis in the rhesus monkey by trilostane. Fertil Steril. 1979;32(4):464-467. 
[3] Lambert F, Corcelle-Cerf  F, Lammerant J, Kolanowski J. On the specificity of the 
inhibitory effect of trilostane and aminoglutethimide on adrenocortical steroidogenesis in 
guinea pig. Mol Cell Endocinol. 1984;37(1):115-120. 
[4] Ruckstuhl NS, Nett CS, Reusch CE. Results of clinical examinations, laboratory tests, and  
ultrasonography in dogs with pituitary-dependant hyperadrenocorticism treated with  
trilostane. Am J Vet Res. 2002;63(4):506-512. 
[5] Neiger R, Ramsey I, O’Connor J, Hurley KJ, Mooney CT. Trilostane treatment of 78 dogs  
with pituitary-dependant hyperadrenocorticism. Vet Rec. 2002;150(26):799-804. 
[6] Braddock JA, Church DB, Robertson ID, Watson AD. Trilostane treatment in dogs with 
pituitary-dependent hyperadrenocorticism. Aust Vet J. 2003;81(10):600-607. 
[7] Witt AL, Neiger R. Adrencorticotropic hormone levels in dogs with pituitary-dependent  
hyperadrenocorticism following trilostane therapy. Vet Rec. 2004;154(13):399-400. 
[8] Sieber-Ruckstuhl NS, Boretti FS, Wenger M, Maser-Gluth C, Reusch CE. Cortisol,  
aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with  
pituitary-dependant hyperadrenocorticism treated with trilostane. Dom Anim Endocrinol.  
2006;31(1):63-75. 
[9] Chapman PS, Kelly DF, Archer J, Brockman DJ, Neiger R. Adrenal necrosis in a dog  
receiving trilostane for the treatment of hyperadrenocorticism. J Sm Anim Pract. 
2004;45(6):307-310. 
[10] Reusch CR, Sieber-Ruckstuhl N, Wenger M, Lutz H, Perren A, Pospischil A.  
 17
414 
415 
416 
417 
418 
419 
420 
421 
422 
423 
424 
425 
426 
427 
428 
429 
430 
431 
432 
433 
434 
435 
436 
437 
438 
Histological evaluation of the adrenal glands of seven dogs with hyperadrenocorticism treated  
with trilostane. Vet Rec. 2007;160(7):219-224. 
[11] Ramsey IK, Richardson J, Lendard Z, Tebb AJ, Irwin PJ. Persistent isolated  
hypocortisolism following brief treatment with trilostane. Aust Vet J. 2008;86(12):491-495. 
[12] Kornbluth AA, Salomon P, Sachar DB, Subramani K, Kramer A, Gray CE, Present DH, 
Chapman ML. ACTH-induced adrenal hemorrhage: a complication of therapy masquerading 
as an acute abdomen. J Clin Gastroenterol. 1990;12(4):371-377. 
[13] Levin TL, Morton E. Adrenal hemorrhage complicating ACTH therapy in Crohn’s 
disease. Pediatr Radiol. 1993;23(6):457-458. 
[14] Rao RH. Bilateral massive adrenal hemorrhage. Med Clin North Am. 1995;79(1):107-
129. 
[15] Wilbur OM, Rich AR. A study of the role of adrenocorticotropic hormone (ACTH) in the  
pathogenesis of tubular degeneration of the adrenals. Bulletin John Hopkins Hosp.  
1953;93(5):321-347. 
[16] Miskowiak B, Kasprzak A, Malendowicz LK. Comparative stereological studies on the  
effects of long term CRF and ACTH treatment on the cortex of the suprarenal gland. J Anat.  
1986;146:167-172. 
[17] Sawchenko PE, Arias C. Evidence for Short-Loop Feedback Effects of ACTH on CRF  
and Vasopressin Expression in Parvocellular Neurosecretory neurons. J Neuroendocrinol.  
1995;7(9):721-731. 
[18] Albertin G, Malendowicz LK, Markowska A, Tortorella C, Nussdorfer GG. The  
Hyerplastic Adrenal Glands of Chronically ACTH-administered Rats Display Enhanced  
Glucocorticoid Secretory Response to Gastric Inhibitory Polypeptide. Biomed Res.  
1999;20(6):315-320. 
[19] Galac S, Buijtels JJ, Mol JA, Kooistra HS. Effects of trilostane on the pituitary  
 18
439 
440 
441 
442 
443 
444 
445 
446 
447 
448 
449 
450 
451 
452 
453 
454 
455 
456 
457 
458 
459 
460 
461 
462 
463 
-adrenocortical and renin-aldosterone axis in dogs with pituitary-dependent hypercortisolism.  
Vet J. 2010;183(1):75-80. 
[20] Keller SM, Keller BC, Grest P, Börger CT, Guscetti F. Validation of tissue microarrays  
for immunohistochemical analyses of canine lymphomas. J Vet Diagn Invest. 2007;19(6):  
652-659. 
[21] Jakob S, Corazza N, Diamantis E, Kappeler A, Brunner T. Detection of apoptosis in vivo  
using antibodies against caspase-induced neo-epitopes. Methods. 2008; 44(3):255-261. 
[22] Slee EA, Adain C, Martin SJ. Serial killers: ordering caspase activation events in  
apoptosis. Cell Death Differ. 1999;6(11):1067-1074. 
[23] Takahashi A, Alnemri ES, Lazebnik YA, Fernandes-Alnemri T, Litwack G, Moir RD,  
Goldman RD, Poirier GG, Kaufmann SH, Earnshaw WC. Cleavage of lamin A by Mch2  
alpha but not CPP32: multiple interleukin 1 beta-converting enzymes-related proteases with  
distinct substrate recognition properties are active in apoptosis. Proc Natl Acad Sci U S A.  
1996;93(16):8395-8400. 
[24] Bantel H, Lügering A, Poremba C, Lügering N, Held J, Domschke W, Schulze-Osthoff  
K. Caspase activation correlates with the degree of inflammatory liver injury in chronic  
hepatitis C virus infection. Hepatology. 2001:34(4 Pt 1);758-767. 
[25] Bellinger LL, Williams FE, Bernardis LL. Effect of hypophysectomy, thyroidectomy,  
castration and adrenalectomy on diurnal food and water intake in rats. Proc Soc Exp Biol  
Med. 1979;161(2):162-166. 
[26] Castonguay TW, Dallman MF, Stern JS. Some metabolic and behavioral effects of  
adrenalectomy on obese Zucker rats. Am J Physiol. 1986;251(5 Pt 2): R923-933. 
[27] Green PK, Wilkinson CW, Woods SC. Intraventricular corticosterone increases the rate  
of body weight gain in underweight adrenalectomized rats. Endocrinology. 1992;130(1):269- 
275. 
 19
464 
465 
466 
467 
468 
469 
470 
471 
472 
473 
474 
475 
476 
477 
478 
479 
480 
481 
482 
483 
[28] Jungmann E, Magnet W, Rottmann-Kuhnke U, Sprey R, Schwedes U, Usadel K-U,  
Schöffling K. The inhibiting effect of trilostane on adrenal steroid synthesis: hormonal and  
morphological alterations induced by subchronic trilostane treatment in normal rats. Rex Exp 
Red (Berl). 1982;180(2):193-200. 
[29] Kawai K, Baba K, Senba M, Nakamura T, Doi Y, Yamaguchi T, Hashiba K, Tsuchiyama  
H. Effect of the adrenal inhibitor trilostane on the morphology of the adrenocortical cells of  
Dahl salt-sensitive and Dahl salt-resistant rats. Int J Exp Path. 1991;72(4):451-462. 
[30] Sillence MN, Rodway RG. Age- and sex-dependent stimulation of growth rate in rats by  
the adrenal inhibitor trilostane. J Endocriol. 1987;113:479-484. 
[31] Fournié GJ, Courtin JP, Laval F, Chalé JJ, Pourrat JP, Pujazon MC, Lauque D, Carles P. 
Plasma DNA as a marker of cancerous cell death. Investigation in patients suffering from  
lung cancer and in nude mice bearing human tumors. Cancer Lett. 1995;91(2):221-227. 
[32] Amoura Z, Piette JC, Chabre H, Cacoub P, Papo T, Wechsler B, Bach JF, Koutouzov S.  
Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus:  
correlation with serum antinucleosome antibody titers and absence of clear association with  
disease activity. Arthritis Rheum. 1997;40(12):2217-2225. 
[33] Holdenrieder S, Stieber P, Bodenmüller H, Busch M, Fertig G, Fürst H, Schlhorn A,  
Schmeller N, Untch M, Seidel D. Nucleosomes in serum of patients with benign and  
malignant diseases. In J Cancer. 2001;95(2):114-120. 
  
 20
Figure legends: 484 
485 
486 
487 
488 
489 
490 
491 
492 
493 
494 
495 
496 
497 
498 
499 
500 
501 
502 
503 
504 
505 
506 
507 
508 
509 
Figure 1:  
Body weight development in rats treated with either ACTH (a) or trilostane (b). The symbols 
represent the median of each group.   
In the first experiment, the body weight development over time was significantly different 
between all groups except between the rats treated with 20 and 10 μg ACTH/d. 
 
Figure 2: 
Histological section of the adrenal cortex of a rat treated with 60 μg ACTH/d (a) and a control 
rat (b).  
a:  Diffuse hyperemia and hemorrhage and severe focal vacuolization is seen.     
 
Figure 3: 
Scatter plots of the cumulative histologic score, comprising hyperemia/hemorrhage, 
vacuolization and clusters of neutrophils in ACTH-treated rats compared to control rats (a) 
and in trilostane-treated rats compared to control rats (b); the line represents the median of 
each group. ∗ Significant difference. 
 
Figure 4: 
Histological section of the adrenal cortex of a rat treated with 60 µg ACTH/d. Lamin A 
positive cells are stained red. 
 
Figure 5: 
Scatter plots of the number of lamin A positive cells in ACTH-treated rats compared to 
control rats (a) and in trilostane-treated rats compared to control rats (b) and of caspase-3 
positive cells in ACTH-treated rats compared to control rats (c) and in trilostane-treated rats 
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compared to control rats (d); the line represents the median of each group. ∗ Significant 
difference. 
 
Figure 6: 
Scatter plots of the amount of histone-complexed DNA fragments (nucleosomes) in ACTH-
treated rats compared to control rats; the line represents the median of each group. ∗ 
Significant difference. 
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